Efficacy of Zoster Vaccination in Glioblastoma Patients

In modern practice a trimodality treatment has emerged as standard of care for histologically confirmed glioblastoma. We hypothesize that the additional vaccination against herpes zoster, after surgical resection followed by irradiation therapy and chemotherapy of patients with glioblastoma will lead to a superior local control, overall and progression free survival. In an additional experimental setting based on patient preference the immunological effectiveness of the adoptive transfer of autologous polyclonal cytomegalovirus (CMV) specific T cells will be examined.

NCT Number	NCT07546669
Lead Sponsor	University Hospital, Essen Collaborators: Karolinska Institutet, Leiden University Medical Center, Universitätsklinikum Hamburg-Eppendorf
Conditions	Glioblastoma (GBM)
Enrollment	230 participants
Start Date	2027-01-02
Primary Completion	2029-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-04-23